



Association for Multidisciplinary
Education and Research in
Substance use and Addiction



Evaluation of Outcomes of Extended-Release Buprenorphine Administered During Emergency Department and Inpatient Visits

Megan Heeney, MD; Erik Anderson, MD; Lauren Sirey, PharmD; Monish Ullal, MD;
Amy Liang, MD; Robert Benard, NP; Kay Lind, MD; Andrew Herring, MD

Alameda Health System

Department of Emergency Medicine

Division of Addiction Medicine



Association for Multidisciplinary
Education and Research in
Substance use and Addiction



No Conflicts of Interest



Association for Multidisciplinary
Education and Research in
Substance use and Addiction



Background Buprenorphine XR

- 2 Formulations of Bup XR available in the US
- XR Buprenorphine available inpatient and ED at Highland Hospital starting Sept 2023
- Challenges with insurance reimbursement
- Bup XR approximately \$1500
- Benefits for patients with barriers to taking daily meds



Association for Multidisciplinary
Education and Research in
Substance use and Addiction



Background

- XR Bup associated with higher rates of follow up.
- ED INNOVATION demonstrated XR-Bup in ED is safe and well tolerated.
- Patients engaged in ED by Substance Use Navigators had higher rates of 30 day follow up.
- Health disparities around MOUD access.

Lee, et al JNO 2021; O'Connor, et al JAD 2024; Martin et al JSAT 2022;
Hansen, et al JAM 2024; D'Onofrio, et al AEM 2023; Anderson, et al AnEM 2022
Shearer et al DAD R 2023; Kilaru et al JNO 2020

Methods

- Retrospective cohort study of patients receiving XR Bup in ED or Inpatient
 - September 1, 2023 to March 31, 2024
- Primary Outcome: 30 day follow up outpatient for OUD
- Secondary Outcomes: Incidence of buprenorphine precipitated withdrawal



Association for Multidisciplinary
Education and Research in
Substance use and Addiction



Results

- 41 Encounters; 7 ED, 34 Inpatient
- Mean Age 46.6 (SD 12.3)
- 31 Black, 8 White, 2 Latinx
- 39 with public insurance
- 13 were unhoused



Association for Multidisciplinary
Education and Research in
Substance use and Addiction



Results

- 26 Initiated buprenorphine with Low Dose Initiation with agonist
- 8 received XR Bup on day they tolerated SL Bup
- 5 received XR Bup after BPOW
- 2 received XR Bup after IV Bup only

Follow up:

- **29/41(70.7%) had follow up for OUD within 30 days**
- No one in cohort experienced BPOW after XR BUP

Conclusions and Discussion

- Patients who received Bup XR in ED or IP had high rates of follow up
- Bup XR is feasible intervention in the ED/Inpatient
- Multiple treatment pathways to Bup XR
- Impact of multiple contacts with AM Team
- Future work to determine effectiveness and ideal strategies



Association for Multidisciplinary
Education and Research in
Substance use and Addiction



Thank you!
Questions?

